Vistagen Therapeutics, Inc.

VTGN

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Apr 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
PH94B Nasal Spray	Phase 3	Social Anxiety Disorder	-
Placebo Nasal Spray	Phase 3	Social Anxiety Disorder	-
Fasedienol Nasal Spray	Phase 3	Social Anxiety Disorder (SAD)	-
AV-101	Phase 2	Major Depressive Disorder	-
PH94B	Phase 2	Adjustment Disorder With Anxious Mood	-
Fasedienol Nasal Spray - Placebo Nasal Spray	Phase 2	Social Anxiety Disorder	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

April 2026~Fasedienol Nasal Spray - Placebo Nasal Spray

Primary completion for Fasedienol Nasal Spray - Placebo Nasal Spray trial (NCT06809179) in Social Anxiety Disorder

⭐Phase 3

April 2026~Fasedienol Nasal Spray

Primary completion for Fasedienol Nasal Spray trial (NCT06615557) in Social Anxiety Disorder (SAD)

Regulatory Approvals

VTGN News